No profile data available.
NuCana plc (NCNA) is a healthcare company in the additional cancer treatment drugs industry, based in Edinburgh, United Kingdom, with about 10 full-time employees.
It reported revenue of 0 GBP for fiscal year 2025, and net income of -29.35 million GBP. In Q1 2026 (the quarter ended March 31, 2026) revenue was 0 GBP. Its market capitalization was $4.58 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.
NuCana reported 0 GBP in revenue for fiscal year 2025. In Q1 2026 revenue was 0 GBP.
$4.58 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Traws Pharma, Inc. (TRAW), Imunon, Inc. (IMNN), Liminatus Pharma, Inc. (LIMN), PharmaCyte Biotech, Inc. (PMCB).